[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
Prisco
D
D
Dipartimento di Area Critica Medico-Chirurgica, Università di Firenze.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D015897:Comorbidity; D048909:Diabetes Complications; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006349:Heart Valve Diseases / Q000150:complications; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000150:complications; D002546:Ischemic Attack, Transient / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D054833:Isoindoles; D008875:Middle Aged; D010654:Phenylbutyrates / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D054833:Isoindoles; D010654:Phenylbutyrates; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; C020371:indobufen; D001241:Aspirin
Linee guida sulla terapia antitrombotica nella fibrillazione atriale: cosa pensa la Società Italiana Studio Emostasi e Trombosi.